Activation and Inactivation of Immunoglubulin VH Genes
Project Number1R21AI051480-01
Former Number1R01AI051480-01
Contact PI/Project LeaderSEN, RANJAN SEN
Awardee OrganizationBRANDEIS UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by the applicant): Assembly of immunoglobulin heavy chain
(IgH) genes during B cell differentiation requires two recombination events.
First, one of several DH gene segments rearrange to JH gene segments to produce
DJH joins. Second, one of several hundred VH gene segments rearrange to the DJH
join to produce V(D)J recombined alleles. A small proportion of V(D)J
recombined alleles will encode IgH protein. Those cells that make IgH protein
will terminate recombination of the IgH gene, a process referred to as allelic
exclusion. Earlier studies indicate that allelic exclusion operates at the step
of VH to DJH recombination. The mechanism by which VH recombination is stopped
is not known.
In recent studies of the chromatin structure of the IgH locus we found that VH
genes are activated by three distinct mechanisms. The largest VH J558 gene
family, that is at the 5' end of the locus, is activated by IL-7. The 3' -most
VHS, represented by VH8 1X and VHSM7, are activated only in cells that contain
DJH recombined alleles. Genes that lie between VHJ558 and VHSM7, represented by
VH10, are activated in V-abl transformed cells suggesting that they may be
activated by tyrosine kinases.
In this application we propose to rigorously establish mechanisms that activate
the intermediate and 3?-VH genes (Aim 1). We then propose to test the model
that allelic exclusion is a consequence of terminating signals that activate VH
genes (Aim 2). This will be accomplished by a combination of in-vitro and
in-vivo analyses in genetically altered mouse strains.
These studies are important not only for a comprehensive understanding of IgH
gene assembly, but also for insights into the more general question of how
large segments of the genome are activated.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
616845814
UEI
MXLZGAMFEKN5
Project Start Date
01-September-2002
Project End Date
31-August-2004
Budget Start Date
01-September-2002
Budget End Date
31-August-2004
Project Funding Information for 2002
Total Funding
$337,884
Direct Costs
$225,000
Indirect Costs
$112,884
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Allergy and Infectious Diseases
$337,884
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI051480-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI051480-01
Patents
No Patents information available for 1R21AI051480-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI051480-01
Clinical Studies
No Clinical Studies information available for 1R21AI051480-01
News and More
Related News Releases
No news release information available for 1R21AI051480-01
History
No Historical information available for 1R21AI051480-01
Similar Projects
No Similar Projects information available for 1R21AI051480-01